Roivant Sciences Ltd.
ROIV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001635088
In the last 90 days, Roivant Sciences Ltd. insiders filed 0 open-market purchases and 11 sales; 503 institutions reported holding it in 13F filings for Q2 2026, worth $19.7B in total; 3 superinvestors hold it, including Viking Global Investors and Maverick Capital.
Key figures
- Market capClose on Nov 10, 2026
- $29.8B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $74.4M in total
- 11
- 13F holdersQ2 2026, +60 vs. previous quarter
- 503
- 13F valueReported value at the end of Q2 2026
- $19.7B
- Superinvestors holdingAt the end of Q2 2026
- 3
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $8.26M
- −71.6% year over year
- Net income, FY2025
- -$299.8M
- No comparable prior period
- Free cash flow, FY2025
- -$758.6M
- No comparable prior period
- Revenue, Q2 FY2026
- $35.1M
- +2,135.6% year over year
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 45.5M
- Shares sold short
- Change
- +5.21M
- +12.9% vs. previous
- Days to cover
- 6.07
- At average daily volume
Superinvestors holding ROIV, Q2 2026
Go to the superinvestors tab3 superinvestors report holding Roivant Sciences Ltd. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.6%
Roivant Sciences Ltd.'s share of the portfolio
- Shares
- 6,271,467
- Value
- $221.9M
Maverick Capital
Lee Ainslie
0.9%
Roivant Sciences Ltd.'s share of the portfolio
- Shares
- 2,829,024
- Value
- $100.1M
| Superinvestor | Weight | Value |
|---|---|---|
| Greenlight Capital | 1.9% | $76.2M |
Latest insider trades
See all insider tradesOpen-market purchases and sales by Roivant Sciences Ltd. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 5, 2026 (view filing)6:11 PM ET | Nov 3 | 2 days | Venker EricPresident & Immunovant CEO | SSale | −200.0K | $36.31 | −$7.26M | −16.7%999.2K after | 10b5-1 |
| Oct 30, 2026 (view filing)6:29 PM ET | Oct 28 | 2 days | Venker EricPresident & Immunovant CEO | SSale | −200.0K | $36.59 | −$7.32M | −14.3%1.20M after | 10b5-1 |
| Oct 22, 2026 (view filing)6:44 PM ET | Oct 20 | 2 days | Venker EricPresident & Immunovant CEO | SSale | −200.0K | $35.11 | −$7.02M | −12.5%1.40M after | 2 lots10b5-1 |
| Oct 5, 2026 (view filing)6:05 PM ET | Oct 1 | 4 days | Epperly Melissa B,Director | SSale | −17.8K | $36.10 | −$640.9K | −54.3%15.0K after | 2 lots10b5-1 |
| Oct 2, 2026 (view filing)5:37 PM ET | Sep 30 | 2 days | Venker EricPresident & Immunovant CEO | SSale | −200.0K | $36.62 | −$7.32M | −11.1%1.60M after | 10b5-1 |
| Sep 17, 2026 (view filing)6:43 PM ET | Sep 15 | 2 days | Epperly Melissa B,Director | SSale | −4.94K | $39.74 | −$196.2K | −33.3%9.90K after | 2 lots10b5-1 |
| Sep 17, 2026 (view filing)6:42 PM ET | Sep 15 | 2 days | Fitzgerald MeghanDirector | SSale | −5.11K | $39.74 | −$203.2K | −12.4%36.1K after | 2 lots10b5-1 |
| Sep 10, 2026 (view filing)9:00 PM ET | Sep 8 | 2 days | Fitzgerald MeghanDirector | SSale | −20.0K | $39.90 | −$798.0K | −31.8%43.0K after | 10b5-1 |
| Sep 1, 2026 (view filing)9:00 PM ET | Aug 28 | 4 days | Venker EricPresident & Immunovant CEO | SSale | −200.0K | $35.77 | −$7.15M | −11.1%1.60M after | 2 lots10b5-1 |
| Aug 21, 2026 (view filing)9:00 PM ET | Aug 19-21 | 2 days | Sukhatme MayukhPresident & CIO | SSale | −335.2K | $36.88 | −$12.4M | −1.8%18.6M after | 3 lots |
Top 10 13F holders, Q2 2026
See all 503 holdersThe largest institutional positions in Roivant Sciences Ltd. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 81,020,390 | $2.87B | 0.12% | +3,039,137+3.9% | Added |
| BlackRock, Inc. | 48,236,091 | $1.71B | 0.03% | +3,981,831+9.0% | Added |
| Morgan Stanley | 42,592,905 | $1.51B | 0.08% | −9,235,420−17.8% | Reduced |
| QVT Financial LP | 23,723,074 | $839.6M | 53.73% | −1,438,163−5.7% | Reduced |
| Vanguard Capital Management LLC | 22,123,198 | $782.9M | 0.02% | +1,442,626+7.0% | Added |
| Vanguard Portfolio Management LLC | 21,641,339 | $765.9M | 0.03% | +1,802,641+9.1% | Added |
| Goldman Sachs Group Inc | 18,556,458 | $656.7M | 0.07% | +7,444,867+67.0% | Added |
| State Street Corp | 17,795,975 | $629.8M | 0.02% | +1,609,362+9.9% | Added |
| UBS Group AG | 17,466,641 | $618.1M | 0.10% | −5,152,831−22.8% | Reduced |
| Farallon Capital Management, L.L.C. | 14,309,000 | $506.4M | 2.96% | +4,634,000+47.9% | Added |
Holders of 5% or more of ROIV
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Roivant Sciences Ltd..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 11.80%85.6M shares | +1.50 ppfrom 10.30% | Nov 12, 20245 filings | Nov 5, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 8.20%59.3M shares | – | Oct 24, 20243 filings | Oct 27, 2026 | SEC |
| Morgan Stanley | 13G/A | 5.70%40.7M shares | −1.20 ppfrom 6.90% | Aug 7, 20254 filings | Aug 13, 2026 | SEC |
Politician trades
All politician trades in ROIV1 member of Congress reported 4 trades in Roivant Sciences Ltd. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Nov 21, 2025 |  Lisa C. McClain House · MI | Sell | $1K-$15K |
| Nov 21, 2025 | Lisa C. McClain House · MI | Buy | $1K-$15K |
| Nov 21, 2025 | Lisa C. McClain House · MI | Sell | $1K-$15K |
| Aug 13, 2025 | Lisa C. McClain House · MI | Buy | $1K-$15K |
House · MI · Nov 21, 2025
Sell$1K-$15K
House · MI · Nov 21, 2025
Buy$1K-$15K
House · MI · Nov 21, 2025
Sell$1K-$15K
House · MI · Aug 13, 2025
Buy$1K-$15K